Benserazide hydrochloride is under clinical development by Phoenicia Biosciences and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Benserazide hydrochloride’s likelihood of approval (LoA) and phase transition for Beta Thalassaemia took place on 19 Mar 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Benserazide hydrochloride Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Benserazide hydrochloride overview

Benserazide hydrochloride (PB-04) is under development for the treatment of sickle cell disease and beta thalassemia. A drug candidate is a racemate form of a globin gene modulator. Globin modulators are orally-available small molecules for therapeutic activation of developmentally silenced genes. It targets dopa decarboxylase. It is identified using high throughput screening from a compound library.

Quick View Benserazide hydrochloride LOA Data

Report Segments
  • Innovator
Drug Name
  • Benserazide hydrochloride
Administration Pathway
  • Oral
Therapeutic Areas
  • Hematological Disorders
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.